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doi:10.1Objective: Cardiopulmonary bypass remains associated with significant morbidity and mortality, in part caused
by a systemic inflammatory response that is unpredictable and variable among patients. Several limited studies
have suggested associations of cytokine plasma levels or gene polymorphisms with outcome after cardiopulmo-
nary bypass. The present study was to determine the relationships between several circulating cytokines and
their polymorphisms (single nucleotide polymorphisms), and the occurrence of postoperative clinical events
in patients who underwent coronary artery bypass grafting under cardiopulmonary bypass.
Methods: Patients were genotyped for single nucleotide polymorphisms of LTA (Cys13Arg,þ252A>G), TNF
(-308G>A), IL6 (-597G>A, -572G>C, -174G>C), IL10 (-592C>A, c.*117C>T), and APOE (Cys112Arg,
Arg158Cys). Serum samples were collected preoperatively, immediately after cardiopulmonary bypass, and
at different postoperative time points to measure cytokine serum levels by enzyme-linked immunosorbent assay.
The clinical end point was the composite of postoperative death, low cardiac output syndrome, myocardial in-
farction, sepsis, and acute renal insufficiency.
Results: Single nucleotide polymorphisms IL6-572GCþCC/IL10-592CC were associated with the clinical end
point (P¼ .032 and P¼ .009, respectively). In addition to preoperative clinical conditions, the other factor asso-
ciatedwith the clinical endpointwas interleukin-10 plasma levels 24 hours after surgery (P¼ .017).On the basis of
these results, a predictive model of postoperative complications after coronary artery bypass grafting was created.
Conclusions: Our data suggest that focused genetic testing of the IL6-572G>C and IL10-592C>A single nucle-
otide polymorphisms might be a tool for identifying patients at the highest risk of poor tolerance to the inflam-
matory response to cardiopulmonary bypass and for implementing strategies to mitigate it, provided the
generalization of these tests makes them reasonably affordable and thus favorably shifts their cost-to-benefit ra-
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SDespite many improvements over these last decades, cardio-
pulmonary bypass (CPB) still induces an acute inflammatory
response associatedwith significantmorbidity andmortality.1
Disruption in thebalancebetweenpro- and anti-inflammatory
cytokine levels has been suggested to be a key factor of a sys-
temic inflammatory response syndrome (SIRS), resulting in
organ dysfunction affecting the heart, brain, lungs, and kid-
neys. However, the intensity of this inflammatory response
is variable among patients and remains unpredictable.
Unpredictability of the inflammatory response may be
explained by genetic variability. Most studied polymor-
phisms are single nucleotide polymorphisms (SNPs). An
SNP is a genetic variation that occurs when a nucleotide re-
places another one, present in more than 1% of the popula-
tion.Most commonly, these variations are found in the DNA
between genes. When SNPs occur within a gene or in a reg-
ulatory region near a gene, they may play a role in disease
by affecting the gene function. SNPs located in gene pro-
moters can result in an upregulation or downregulation of
the gene expression and then an increase or decrease of
the protein level. Coding SNPs, which lead to an amino
acid substitution, can affect the protein function.rdiovascular Surgery c Volume 144, Number 2 467
Abbreviations and Acronyms
ARI ¼ acute renal insufficiency
CABG ¼ coronary artery bypass grafting
CE ¼ clinical end point
COPD ¼ chronic obstructive pulmonary disease
CPB ¼ cardiopulmonary bypass
IL ¼ interleukin
ITA ¼ internal thoracic artery
LCOS ¼ low cardiac output syndrome
LVEF ¼ left ventricular ejection fraction
MI ¼ myocardial infarction
SIRS ¼ systemic inflammatory response
syndrome
SNP ¼ single nucleotide polymorphism
TNF ¼ tumor necrosis factor
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SSeveral studies have shown associations between cyto-
kine plasma levels or gene polymorphisms and clinical
outcome after CPB, but these studies often focused on
a single cytokine2-5 or one clinical complication.6 In an at-
tempt to overcome these limitations, we carried out a pro-
spective study on a cohort of patients undergoing coronary
artery bypass grafting (CABG) under CPB and evaluated
the impact of gene polymorphisms encoding proinflam-
matory (interleukin [IL]-6 and tumor necrosis factor
[TNF]-a) and anti-inflammatory (IL10) cytokines, as
well as the corresponding plasma levels, on postoperative
complications. The overall objective was to assess
whether a focused genetic screening could help identify
patients at high risk of developing post-CABG inflamma-
tory complications.MATERIALS AND METHODS
Patient Population
A single-center prospective study was carried out in a cohort of 126 pa-
tients undergoing CABG under CPB. This study was approved by our local
ethics committee. All patients provided informed consent. All patients
aged more than 20 years, referred for CABG under CPB and cardiac arrest,
were included. Exclusion criteria were age greater than 80 years, emer-
gency surgery, associated surgical procedures, left ventricular ejection
fraction (LVEF) less than 30%, nonsteroidal anti-inflammatory drug or
corticosteroid use, preoperative dialysis, redo-surgery, single-vessel dis-
ease, hepatic insufficiency, and current infection. Chronic renal insuffi-
ciency and preoperative symptomatic cardiac insufficiency, defined by
the association of LVEF less than 50% and dyspnea New York Heart As-
sociation class III/IV or recent hospitalization requirement for pulmonary
edema, were not exclusion criteria.
Surgical Procedure
Patients were operated via a midline sternotomy, and CPB was per-
formed under normothermia between 34C and 37C. Cardiac arrest was
obtained by normothermic, intermittent antegrade or continuous retro-
grade, whole blood cardioplegia. All patients underwent the implantation
of an internal thoracic artery (ITA) on the left descending coronary artery.468 The Journal of Thoracic and Cardiovascular SurgAdditional bypasses were done with the use of ITA, radial artery, or saphe-
nous vein conduits.
Definitions of the Clinical End Point
The clinical end point (CE) included postoperative death from any
cause, myocardial infarction (MI), low cardiac output syndrome (LCOS),
stroke, acute renal insufficiency (ARI), or sepsis. Death was reported if it
occurred within 30 days or at any time during hospital admission. MI
was defined as typical electrical changes on postoperative electrocardio-
gram or abnormal changes in wall motion on echocardiography and post-
operative cardiac troponin I plasma levels greater than 15 mg/L at any time
after surgery. LCOS was defined by the requirement for mechanical assis-
tance or prolonged inotropic support (epinephrine or dobutamine>5 mg/
kg/min for> 30 minutes in the intensive care unit) to maintain systolic
blood pressure greater than 90 mm Hg or cardiac index greater than 2.2
L/m2. Stroke was reported if any clinical suspicion of cerebral ischemic
symptoms lasting more than 24 hours was confirmed by computed tomog-
raphy. Acute renal insufficiency was defined as plasma creatinine levels
greater than 200 mmol/L or, particularly for patients having a baseline
plasma creatinine level greater than 150 mmol/L, the requirement for hemo-
dialysis at any time after surgery. Sepsis encompassed several components
(pneumonia, pyelonephritis, mediastinitis, or superficial wound infection).
Cytokine Measurements
IL10 and IL6 plasma levels were measured by ELISA (Diaclone, Be-
sanc¸on, France). An ultrasensitive TNFa ELISA (R&D Systems, Lille,
France) was used for TNFameasurement as previously described.7 Assays
were performed at 3 time points: before anesthesia, at the end of CPB
(IL10) or 4 hours thereafter (IL6 and TNFa), and 24 hours after CPB.
The end-CPB and 4-hour post-CPB study points were selected on the basis
of previous studies showing that they correspond to peak levels for IL10 or
IL6 and TNFa, respectively.7,8
Selection of Candidate Genes and Polymorphisms
Five candidate genes involved in the pathogenesis of inflammation were se-
lected on the basis of pathway analysis and a review of association studies re-
ported in the literature.2,3,9-11 The objective was not to capture a high
proportion of genetic information at each locus, but rather to concentrate on
SNPs previously associated with the trait, with an emphasis on their minor
allele frequency (5% except for one), or those previously shown to be
functional.4,12-14 The 10 selected SNPs were IL10-592C>A, c.*117C>T, IL6-
597G>A, -572G>C, -174G>C, TNF-308G>A, LTAþ252A>G, Cys13Arg,
and the 2 polymorphisms determining ε2, 3, and 4 alleles of the APOE gene
(Table E1). This limited number of SNPs also had the advantage of not weak-
ening the power of the statistical analysis by testing many associations.
Genomic DNA Isolation and Genotype Analysis
Genomic DNAwas isolated from peripheral blood leukocytes, collected
preoperatively from blood samples, by proteinase K digestion and saline
extraction. TNF-308G>A and LTAþ252A>G were genotyped by polymer-
ase chain reaction-restriction fragment length polymorphism with NcoI re-
striction enzyme (Promega Corp, Madison, Wis) according to the
manufacturer’s instructions. Other SNPs were genotyped by direct se-
quencing using kits and run on a 3730 DNA analyzer (Applied Biosystems,
Carlsbad, Calif), and DNA sequences were analyzed by the Sequencher
software (Gene Codes Corporation, Ann Arbor, Mich) (Table E2). Geno-
type distribution did not differ significantly from that predicted by the
Hardy–Weinberg equilibrium law for each polymorphism.
Statistical Analysis
Descriptive statistics usedmeans and standard deviations for quantitative
variables and numbers and percentages for qualitative variables. Hardy–
Weinberg equilibrium of genotypes was tested using chi-square tests.ery c August 2012
TABLE 1. Preoperative and perioperative patient characteristics
CE No CE P
n (%) 18 (14) 108 (86)
Preoperative characteristics
Age 67.3  9.5 63.4  9.0 .11
Gender M/F (% male) 16/2 (89) 95/13 (88) NS
BMI 25.7  3.6 27.0  3.7 NS
Cardiovascular risk factors
Diabetes mellitus 4 (22) 31 (29) NS
Hypertension 13 (72) 69 (64) NS
Hypercholesterolemia 15 (83) 88 (81) NS
Tobacco consumption 4 (22) 29 (27) NS
COPD 5 (28) 11 (10) .06
Previous MI 8 (44) 39 (36) NS
Preoperative symptomatic
Cardiac insufficiency
5 (28) 2 (2) 7.104
Treated atrial fibrillation 2 (11) 4 (4) NS
LVEF 30%–50% 5 (28) 10 (9) .05
Intraoperative characteristics
Operative duration (h) 4.2  0.8 4.0  0.8 NS
CPB duration (h) 1.6  0.4 1.5  0.5 NS
Aortic clamp duration (h) 0.9  0.4 0.9  0.3 NS
Lowest temperature under
CPB (C)
35.1  0.6 35.1  0.9 NS
BMI, Body mass index; NS, not significant.
TABLE 2. Risk factors for clinical complications according to clinical
end point
CE n (%)
or median
(Q1–Q3)
No CE n (%)
or median
(Q1–Q3)
Univariate
P (Bonferroni P)
Age (/10) 6.80 (6.10–7.60) 6.30 (5.65–7.00) .106
COPD 5 (27.8) 11 (10.2) .054
Preoperative
symptomatic
cardiac
insufficiency
5 (27.8) 2 (1.9) 7.104
LVEF 30%–50% 5 (27.8) 10 (9.3) .041
IL6–572G>C*
GG 12 (66.7) 96 (88.9) .032
GC 6 (33.3) 10 (9.3) (.32)
CC 0 (0.0) 2 (1.9)
IL10–592C>A*
CC 16 (88.9) 54 (50.0) .009
CA 2 (11.1) 44 (40.7) (.09)
AA 0 (0.0) 10 (9.3)
24–h IL10
concentration
11.0 (2.0–37.0) 2.0 (0.0–9.0) .017
*For multivariable analysis, IL6-572G>C is coded (GC or CC ¼ 1, GG ¼ 0) and
IL10-592C>A is coded (CC ¼ 1, CA or AA ¼ 0).
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SThe statistical analysis was performed using 2 steps. In the first step,
a univariate analysis aimed at assessing risk factors of CE was performed.
This analysis embedded a genotype–phenotype association study. Geno-
types were coded as qualitative variables, with 3 or 2 modalities, assuming
a dominant effect. The univariate analysis was based on 2-sample Wil-
coxon tests for quantitative data and chi-square or Fisher exact tests,
when chi-square tests were not valid, for qualitative data. A Bonferroni cor-
rection was applied for genotypes.
In the second step, variables associated with CE in the univariate anal-
ysis with a P value less than .20 were included in a stepwise logistic regres-
sion to build a predictive model of complications. Variables retained in the
final model had a P value less than .05 using theWald test and were used for
building a predictive score. A score threshold was determined arbitrarily to
define a high-risk group. Evaluation of the predictive power of the model
was based on the area under the receiver operating characteristic curve,
sensitivity, specificity, positive and negative predictive values, and relative
risk of complications between the high-risk and low-risk groups. These pa-
rameters, a part area under the receiver operating characteristic curve, were
first computed on the sample, and in a second step their means and 95%
confidence intervals were estimated by nonparametric Bootstrap, involving
10,000 Bootstrap samples. Confidence intervals were determined using 2.5
and 97.5 percentiles of the Bootstrap sample distribution.
Relationships between cytokine log-concentrations and covariates were
tested, in a univariate step, using 2-sample Wilcoxon tests for binary cova-
riates, nonparametric analyses of variance (Kruskal–Wallis tests) for other
qualitative covariates, including genotypes, and Spearman-rank correlation
coefficient tests for quantitative covariates. The corresponding multivari-
able analyses were performed using mixed linear models with a log-
transformation of the data to normalize the residuals and fit the model
assumptions. The cytokine kinetics (3 log-concentrations by subject)
were analyzed using mixed linear models, with log-concentrations consid-
ered as repeated data. All tests were 2-sided. Computations were performed
using the SAS v9 statistical package (SAS Institute Inc, Cary, NC).
RESULTS
Clinical Events
Patient characteristics are summarized in Table 1. Proce-
dures included 2, 3, or 4 CABGs in 35 patients (28%), 73
patients (58%), and 18 patients (14%), respectively. Revas-
cularization was exclusively done with the 2 ITAs in 26 pa-
tients (21%). Intrathoracic arterial balloon pump or
inotropic support was required for weaning from CPB in
2 patients (2%) and 16 patients (13%), respectively. Perio-
perative red blood cell transfusions were needed in 45 pa-
tients (36%). Mean intensive care unit length of stay was
2.2  3.9 days, and mean duration under mechanical venti-
lation was 19.9  63.9 hours.
Of the 126 patients, 18 (14.3%) experienced any one of the
clinical complications included in CE. Complications included
were 4 deaths (3.2%), 7 MIs (5.6%), 11 cases of LCOS
(8.7%), 8 cases of ARI (6.3%), and 10 cases of sepsis
(7.9%). There was no stroke. Clinical conditions associated
with CE were chronic obstructive pulmonary disease (COPD)
(P ¼ .054), preoperative symptomatic cardiac insufficiency
(P¼ 7.104), and LVEF less than 50% (P¼ .041) (Table 2).
Cytokine Circulating Levels and Their Association
With Genetic Polymorphisms
Plasma levels of IL10, IL6, and TNFa were elevated at
the end of CPB (IL10) or 4 hours thereafter (IL6 andThe Journal of Thoracic and CaTNFa) and decreased 24 hours after CPB (P < 104)
(Figure 1). Cytokine plasma levels 24 hours after CPB re-
mained higher (IL6, P< 104) or were not significantly
higher (IL10 and TNFa) than baseline levels. IL10 plasma
levels 24 hours after CPB were found to be significantly as-
sociated with CE (P ¼ .017) (Figure 2, Table 2).rdiovascular Surgery c Volume 144, Number 2 469
FIGURE 1. Perioperative cytokine plasma levels.CPB,Cardiopulmonary
bypass; IL, interleukin; TNF, tumor necrosis factor.
FIGURE 3. Relations between SNPs and CE. A, SNP IL6-572G>C.
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with gene polymorphisms (Table E3), IL10 plasma levels
24 hours after CPB were found to be associated with SNP
IL6-572G>C; patients with IL6-572CC genotype had the
highest IL10 levels (P ¼ .040). IL6 plasma levels 24 hours
after CPB were associated with APOE polymorphism; pa-
tients with APOE3/3 genotype had lower IL6 levels than
those with APOE3/4 or 3/2 genotypes (P ¼ .011 and
P ¼ .027 in univariate and multivariable analyses, respec-
tively). A weak association was observed between TNFa
plasma levels before anesthesia and SNP TNF-308G>A;
patients with TNF-308AA genotype had the lowest TNFa
levels (P ¼ .073 and P ¼ .039 in univariate and multivari-
able analyses, respectively). When analyzed over the 24-
hour kinetics, TNFa plasma levels were associated with
SNP LTA Cys13Arg (P ¼ .019); patients with LTA 13Ar-
gArg genotype had the highest TNFa plasma levels beforeFIGURE 2. Perioperative IL10 plasma levels and the occurrence of clin-
ical complications according to the CE. Error bars represent the standard
error of the mean. CPB, Cardiopulmonary bypass.
B, SNP IL10-592C>A. CE, Clinical end point.
470 The Journal of Thoracic and Cardiovascular Surganesthesia and 24 hours after CPB, but TNFa levels 4 hours
after CPB were similar for the 3 genotypes.Genetic Polymorphisms and Postoperative Adverse
Events
Genetic polymorphisms associated with CE were SNPs
IL6-572G>C and IL10-592C>A, because a higher number
of complications included in this end point was seen in pa-
tients with IL6-572GC or CC genotypes (OR, 8.5; P¼ .004)
or the IL10-592CC genotype (OR, 11.4; P ¼ .009). How-
ever, these observations were not supported after Bonfer-
roni correction (Figure 3, A and B, Table 2).Predictive Model
We defined a prediction score for patients at high risk
of complications. The predictive score formula wasery c August 2012
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2.43 (IL10-592CC)þ23 (COPD)þ4.33 (treated cardiac
insufficiency).
A score greater than0.65 had a 68% predictive positive
value, a 95% predictive negative value, a 72% sensitivity,
a 94% specificity, and a relative risk of 14.64. These predic-
tive parameters were estimated by bootstrap (n ¼ 10,000).
Bootstrap parameters had a mean and 95% confidence in-
terval of 68 (45–88), 95 (91–99), 71 (48–92), 94 (89–98),
and 20.71 (5.73–96.25), respectively.
DISCUSSION
The CPB-induced SIRS has been widely studied for
many years. It has now been convincingly demonstrated
that this SIRS involves at least 3 interconnected plasma pro-
tease pathways: the complement cascade, cellular re-
sponses, and cytokine secretion.8 More recently, several
studies have shown conflicting results concerning the influ-
ence of genetic polymorphisms on cytokine release and the
related magnitude of this inflammatory response.2,15 By
using a relatively large group of patients who underwent
CABG, a strict standardized procedure, and definition of
the CE, we show that 2 cytokine polymorphisms (IL6-
572G>C and IL10-592C>A) and IL10 serum level 24
hours after CPB seem to influence the occurrence of
adverse outcomes after CABG surgery under CPB.
Death has now become rare after CABG surgery (1%–
3%), but the rate of postoperative complications still varies
between 10% and 30%. In our study, death occurred in 4
patients (3.1%) and CE occurred in 18 patients (14.3%),
with ARI in 6.4% and MI in 5.6%. Our data stand above
the median rate of complications reported in a meta-
analysis including more than 200,000 patients among 176
series of patients undergoing CABG.16 These differences
can be explained by the definitions of complications. Actu-
ally, ARI after CABG varies from 0% to 6.2% and MI
varies from 0% to 29%. Our definitions of ARI and MI
were among the most sensitive in the literature. Cardiac tro-
ponin I plasma levels have been shown to be the most rele-
vant markers to assess MI after revascularization, over
electrocardiogram changes and creatine kinase-MB.17 In
addition, recent cohort studies suffer from the lack of pa-
tients displaying a dysmetabolic syndrome, including vari-
ous metabolic risk factors such as abdominal obesity,
dyslipidemia, hypertension, and hyperglycemia, which are
thought to be linked to insulin resistance.18 These patients
are now increasingly referred for CABG and are prone to
develop more postoperative ARIs and MIs.19
Cytokines and Clinical Outcomes
In this study, proinflammatory (IL6 and TNFa) and anti-
inflammatory (IL10) plasma levels increased after CPB and
decreased 24 hours later, as described in previous studies.20
IL6 and TNFa have been shown to be key mediators ofThe Journal of Thoracic and CaSIRS after CPB.8 IL10 is an anti-inflammatory cytokine,
which, in contrast, is expected to exert a protective effect
on the outcome after CPB.21 However, several studies
have suggested that high IL10 plasma levels could also re-
sult in an immune ‘‘hyporesponsiveness,’’ leading to
a higher risk of postoperative infectious complications.5 In-
deed, we observed more clinical complications in patients
with highest IL10 plasma levels 24 hours after CPB.
In 1996, Rao and colleagues22 reported a 9.1% rate of
LCOS after CABG in a large adult population. Our series
confirm that LCOS remains one of the major severe compli-
cations after surgical coronary revascularization. Although
LCOS and MI may be related to periprocedural factors,
such as inadequate myocardial protection, a correlation be-
tween postoperative IL6 and IL10 plasma levels and post-
operative myocardial injury has been noted by Giomarelli
and colleagues.23 Our data could not confirm this specific
finding because LCOS and MIs were not separately ana-
lyzed from the other components of our CE. However, it
is conceivable that a higher IL10 response reflects the oc-
currence of a greater inflammatory insult to counteract,
which would be consistent with the observation that these
high IL10 levels were associated with severe complications.
Single Nucleotide Polymorphisms and Clinical
Outcomes
In this study, we observed an association between clinical
complications after CPB and 2 cytokine gene polymor-
phisms, SNPs IL6-572G>C and IL10-592C>A. The SNP
IL6-572G>C has been associated with several cardiovascu-
lar disorders, such as coronary heart disease10 and abdomi-
nal aortic aneurysms.24 Furthermore, Jia and colleagues10
demonstrated a correlation between this SNP and postoper-
ative MI after cardiac surgery under CPB. Our data suggest
that IL6-572G>C is more generally associated with an ad-
verse postoperative course; patients bearing the IL6-
572GC and IL6-572CC genotypes have a 9-fold increased
risk of experiencing one of the complications included in
our CE. In contrast with the study by Brull and colleagues,2
a significant association between SNP IL6-572G>C and
IL6 plasma levels was not observed in our study. The study
published in 2000 by Terry and colleagues4 could explain
this discordance. These authors showed a cooperative influ-
ence of various genetic polymorphisms on IL6 transcrip-
tional regulation. These polymorphisms were located in
the IL6 gene promoter and included SNP IL6-572G>C. In
addition, cytokines are most often present in the serum com-
plexed to their soluble receptors. Wemeasured the total pro-
duction of IL6, because both the free form and that
complexed to its receptor are active, whereas in other stud-
ies the dosage of IL6 only detected the free form of IL6.25
This technical variation in the dosage of IL6 may explain
discrepancies in the reported correlation between IL6 serum
levels and SNPs for this cytokine. Nevertheless, we didrdiovascular Surgery c Volume 144, Number 2 471
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plasma levels 24 hours after CPB, and these 2 factors were
also, in this study, independently associated with clinical
complications.
The SNP IL10-592C>A is in strong linkage disequilib-
rium with 2 other SNPs located in the IL10 gene promoter,
IL10-1082G>A and 819C>T. Haplotype IL10-1082G/-
819C/-592C has been associated with higher IL10 plasma
levels after pediatric cardiac surgery with CPB, and higher
IL10 levels were associated with clinical immunoparalysis,
suggesting a higher risk of postoperative infectious compli-
cations.5 These data are consistent with the association that
we observed between the IL10-592CC genotype and
a higher risk of clinical complications according to our
CE, which included sepsis. No association was found be-
tween SNP IL10-592C>A and IL10 plasma levels, but
this SNP was associated with clinical complications, as
were IL10 plasma levels 24 hours after CPB.
After Bonferroni correction, which is usually required in
case of SNP statistical analyses, these 2 associations
seemed to be weakened. Nevertheless, our results showed
that the association of SNPs IL6-572G>C and IL10-
592C>A, along with IL10 plasma level at 24 hours, preex-
isting COPD or cardiac insufficiency, and age could be
predictive of complications after CABG surgery. If con-
firmed, this predictive model could have implications in
the pre- and postoperative management of specific high-
risk patients.
Study Limitations
We acknowledge that this study has some limitations.
First, small sample sizes conducted us to correlate the var-
ious SNPs with the composite end point, thus making it dif-
ficult to assess the specific impact of the genetic pattern on
a given postoperative complication. This was unavoidable
because the low incidence of individual events required
them to be grouped into a composite criterion to provide
an adequate statistical power. However, from a merely clin-
ical standpoint, the conclusions remain relevant by showing
that the genetic profile allowed the identification of patients
at risk of poor bypass-related outcomes, even though the
specific component driving the composite end point re-
mains elusive. Second, SIRS may not be always advocated
as the cause for some complications of our composite end
point. For example, inadequate myocardial protection could
lead to postoperative MI or LCOS. However, warm blood
cardioplegia (antegrade or retrograde) was consistently
used in all patients, which should have contributed to opti-
mize myocardial protection.26 Third, this genetic profiling
was restricted to a limited number of SNPs. This choice
may look oversimplistic in view of the multiplicity of inter-
mingling pathways involved in the genesis of the post-CPB
inflammatory response; however, it was dictated by previ-
ous published data that identified the selected markers as472 The Journal of Thoracic and Cardiovascular Surgkey players in this response but clearly do not exclude
that other SNPs may have a greater predictive value.CONCLUSIONS
Overall, our data suggest that focused genetic testing of
the IL6-572G>C and IL10-592C>A SNPs might be a tool
for identifying patients at the highest risk of poor tolerance
to the inflammatory response to CPB and for possibly im-
plementing strategies to mitigate it, such as off-pump sur-
gery, drugs, or device-based interventions.27 However,
this first requires that the generalization of these genetic di-
agnostic tests makes them reasonably affordable and thus
favorably shifts their cost-to-benefit ratio.
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TABLE E2. Primers used for genotype analysis
Primer Sequence 50/ 30 Amplicon length (bp) Annealing T ( C)
IL6-F TGGCAAAAAGGAGTCACACA 659 64
IL6-R GCCTCAGACATCTCCAGTCC
IL6-Fint CAAGACATGCCAAAGTGCTG
IL6-Rint GAGTTTCCTCTGACTCCATCG
IL10-592-F CTGTGCCTCAGTTTG CTCAC 487 61
IL10-592-R CCTCAGCTGTGGGTTCTCAT
IL10*117-F GGAGAACAAGCAACCTCTGC 592 61
IL10*117-R AGCTAG AAAGCGTGGTCAGG
LTACys13Arg-F TGTCTCCCTCTGCTCACCTT 338 67
LTACys13Arg-R GGCTCTAGGGCTCAAGGTTT
APOE-F TGAAGGAGTTGAAGGCCTAC 502 58
APOE-R TGCTCCTTCACCTCGTCCAG
TNF-F AGGCAATAGGTTTTGAGGGCCAT 107 60
TNF-R TCCTCCCTGC TCCGATTCCG
LTAþ252-F CCGTGCTTCGTGCTTTGGACTA 782 54
LTAþ252-R AGAGGGGTGGATGCTTGGGTTC
bp, Base pair; T, temperature; F, forward; R, reverse; int, internal sequencing primer.
TABLE E1. Genetic polymorphisms evaluated in the study
Gene (symbol)
Nucleotide
substitution
Genomic
context
SNP
identification*
Cytogenetic
locus
Minor allele
frequency
Hardy–Weinberg
P
Interleukin 6 (IL6) 597G>A 50UTR rs1800797 7p15.3 0.306 .246
572G>C 50UTR rs1800796 0.079 .141
174G>C 50UTR rs1800795 0.310 .655
Interleukin 10 (IL10) 592C>A 50UTR rs1800872 1p32.1 0.262 .532
*117C>T 30UTR rs3024496 0.437 .467
Tumor necrosis
factor–a (TNFa)
308G>A 50UTR rs1800629 6p21.33 0.135 .823
Lymphotoxin alpha (LTA) þ252A>Gy intron 1 rs909253 6p21.33 0.333 .423
37T>C Cys13Arg rs2229094 0.254 .596
Apolipoprotein E (APOE) 388T>C Cys130Arg rs429358 19q13.32 e2: 0.044 .433
526C>T Arg176Cys rs7412 e4: 0.115
UTR, Untranslated region. *From the National Center for Biotechnology Information’s dbDNP public database (http://www.ncbi.nlm.nih.gov/SNP/). yNotation most used in
association studies. The HGVS nomenclature is c.-10þ90A>G.
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TABLE E3. Cytokine plasma levels and polymorphism associations Cytokine levels and polymorphism associations (at each cytokine
measurement)
Cytokine measure SNP Median (Q1–Q3) per genotype
Univariate
P
Multivariable
P
(TNFa) before CPB LTA Cys13Arg CysCys CysArg ArgArg .097 NS
1.0 (0.0–2.0) 1.0 (0.0–2.0) 2.0 (1.0–4.0)
TNF308G>A GG GA AA .073 .039
1.0 (1.0–2.0) 1.0 (0.0–1.0) 0.5 (0.0–1.0)
(IL6) 4 h after CPB IL6174G>C GG GC CC .056 NS
91 (68–159) 106 (73–165) 63 (48–105)
TNF308G>A GG GA AA .099 NS
93 (68–145) 139 (73–171) 169 (155; 183)
(IL6) 24 h after CPB IL6597G>A GG GA AA .054 NS
58.5 (41.5–81) 67 (51–115) 49.5 (37–63)
IL6174G>C GG GC CC .059 NS
58 (42–81) 68 (50–114) 53 (43–62)
APOE alleles 3 0 1 2 .011 .027
46 (38–53) 91 (53–121) 59 (38–74)
(IL10) 24 h after CPB IL6572G>C GG GC CC .040 NS
2 (0–10) 7 (2–16) 78 (34–122)
(TNFa) 24 h after CPB LTA Cys13Arg CysCys CysArg ArgArg .088 NS
1.0 (0.0–3.0) 2.0 (1.0–2.0) 3.0 (2.0–4.0)
Cytokine kinetic and polymorphism associations
SNP Genotype
(IL6) (mean ± SD)
P1 P2Before CPB 4 h after CPB 24 h after CPB
APOE alleles 3 0 3.0  2.8 52.0  15.6 45.5  10.6 .048 NS
1 3.8  9.7 122.2  61.0 99.2  68.5
2 4.6  23.8 131.5  160.5 64.9  39.6
SNP Genotype
(TNFa) (mean ± SD)
P1 P2before CPB 4 h after CPB 24 h after CPB
TNF308G>A GG 1.7  2.6 4.4  4.0 2.1  3.3 .056 NS
GA 1.0  1.3 4.3  4.7 2,6  6.7
AA 0.5  0.7 5.0  1.4 1.0  1.4
LTA Cys13Arg CysCys 1.2  1.2 4.4  4.1 2.2  4.6 .019 NS
CysArg 1.7  3.4 4.4  4.3 2.1  4.1
ArgArg 3.0  2.9 4.3  3.5 3.4  2.6
NS, Not significant; P1, genotype effect; P2, genotype 3 kinetics interaction; SD, standard deviation. Concentration unit is pg/mL.
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